Revue de la littératureTraitement chirurgical des tumeurs endocrines gastro-entéro-pancréatiques: 2. Traitement des métastases hépatiquesSurgical treatment of gastric, enteric and pancreatic endocrine tumors Part 2. Treatment of Hepatic Metastases
Références (142)
- et al.
Management of neuroendocrine liver metastases
Am J Surg
(2004) - et al.
Hepatic neuroendocrine metastases: does intervention alter outcomes?
J Am Coll Surg
(2000) - et al.
The surgical management of pancreatic neuroendocrine tumors
Surg Clin North Am
(2001) - et al.
Liver resection (and associated extrahepatic resections) for metastatic well-differentiated endocrine tumors: a 15-year single center prospective study
Surgery
(2003) - et al.
Surgical treatment of neuroendocrine metastases to the liver: a plea for resection to increase survival
J Am Coll Surg
(2003) - et al.
Carcinoid tumors: analysis of prognostic factors and survival in 301 patients from a referral center
Ann Oncol
(1997) - et al.
Determinants of metastatic rate and survival in patients with Zollinger-Ellison syndrome: a prospective long-term study
Gastroenterology
(1995) - et al.
Hepatic surgery for metastases from neuroendocrine tumors
Surg Oncol Clin N Am
(2003) - et al.
The antitumoral effect of the long-acting somatostatin analog lanreotide in neuroendocrine tumors
Am J Gastroenterol
(2000) - et al.
Usefulness of intraoperative radiofrequency thermoablation of liver tumours associated or not with hepatectomy
Eur J Surg Oncol
(2000)
Liver abscess formation after local treatment of liver tumors
Hepatology
Seven hundred forty-seven hepatectomies in the 1990s: an update to evaluate the actual risk of liver resection
J Am Coll Surg
Resection of liver metastases from colorectal cancer: the real impact of the surgical margin
Eur J Surg Oncol
Resection of liver metastases from a noncolorectal primary: indications and results based on 147 monocentric patients
J Am Coll Surg
Hepatectomy for liver metastases from breast cancer
Eur J Surg Oncol
Hepatic resection for noncolorectal, nonneuroendocrine metastases: a fifteen-year experience with ninety-six patients
Surgery
Isolated liver metastases from neuroendocrine tumors: does resection prolong survival?
J Am Coll Surg
Right portal vein ligation: a new planned two-step all-surgical approach for complete resection of primary gastrointestinal tumors with multiple bilateral liver metastases
J Am Coll Surg
Liver transplantation for neuroendocrine tumors
J Gastrointest Surg
Nonfunctioning islet cell carcinoma of the pancreas: survival results in a contemporary series of 163 patients
Surgery
Result of liver resection as treatment for metastases from noncolorectal cancer
J Surg Oncol
Karnofsky memorial lecture. An odyssey in the land of small tumors
J Clin Oncol
Hepatic resection for metastatic neuroendocrine carcinomas
Am J Surg
Neuroendocrine metastases of the liver
World J Surg
Medical treatment and long-term survival in a prospective study of 84 patients with endocrine pancreatic tumors
Cancer
Prospective study of the clinical course, prognostic factors, causes of death, and survival in patients with long-standing Zollinger-Ellison syndrome
J Clin Oncol
Pancreatic endocrine tumors: recent advances
Ann Oncol
Natural history of neuroendocrine enteropancreatic tumors
Digestion
[Chemotherapy of neuroendocrine tumors]
Rev Prat
Treatment of neuroendocrine carcinomas with combined etoposide and cisplatin. Evidence of major therapeutic activity in the anaplastic variants of these neoplasms
Cancer
Treatment of poorly differentiated neuroendocrine tumours with etoposide and cisplatin
Br J Cancer
[Treatment of pancreatic-duodenal endocrine tumors]
Rev Prat
Trans-catheter arterial chemoembolization as first-line treatment for hepatic metastases from endocrine tumors
Eur Radiol
Prise en charge des tumeurs endocrines duodéno-pancréatiques
J Chir
Clinical efficacy of octreotide in the treatment of metastatic neuroendocrine tumors. A study by the Italian Trials in Medical Oncology Group
Cancer
[Biotherapy of neuroendocrine tumors]
Rev Prat
Randomized clinical trial of the effect of interferon alpha on survival in patients with disseminated midgut carcinoid tumours
Br J Surg
[Chemotherapy of neuroendocrine tumors]
Rev Prat
Streptozocin plus fluorouracil versus doxorubicin therapy for metastatic carcinoid tumor
J Clin Oncol
The management of patients with advanced carcinoid tumors and islet cell carcinomas
Ann Intern Med
[Adjuvant treatment of endocrine digestive tumors]
Gastroenterol Clin Biol
Hepatic arterial chemoembolization in the management of advanced digestive endocrine tumors
Digestion
[Locoregional therapy of neuroendocrine tumors]
Rev Prat
Intra-arterial cis-platinum in osteosarcoma
Haematol Blood Transfus
Hepatic arterial chemoembolization in patients with liver metastases of endocrine tumors. A prospective phase II study in 24 patients
Cancer
Hepatic arterial chemoembolization in the management of advanced digestive endocrine tumours
Ital J Gastroenterol Hepatol
Hepatic arterial chemoembolization with streptozotocin in patients with metastatic digestive endocrine tumours
Eur J Gastroenterol Hepatol
Transcatheter chemoembolization of progressive carcinoid liver metastasis
Radiology
Cited by (20)
Liver transplantation for the treatment of neuroendocrine liver metastases
2016, Best Practice and Research: Clinical Endocrinology and MetabolismCitation Excerpt :Systemic chemotherapeutic agents such as streptozotocin, doxorubicin, or 5-fluorouracil, have been established as treatment options mainly for metastatic pancreatic NETs with variable response rates [14]. In some instances systemic chemotherapy has been able to control symptomatic patients of hormone producing tumors when other modalities have failed [15,16]. Molecular targeted therapies have been utilized to treat patients with advanced NET metastases.
Liver transplantation for metastatic neuroendocrine tumors
2014, Advances in SurgeryCitation Excerpt :This novel therapeutic modality has been proposed for both symptom control and antiproliferative treatment [25]. Palliative surgery, or debulking operations, for symptom control may be undertaken in limited circumstances for the treatment of functioning tumors for which other treatment modalities have failed to control debilitating symptoms [13,26,27]. Although there is no consensus on the percentage of tumor to be removed in order to achieve symptom control, it is possible to achieve greater than 90% tumor volume removal with the combination of resection and ablative therapies [1,13,28].
Neuroendocrine gastro-entero-pancreatic tumors: ESMO clinical practice guidelines for diagnosis, treatment and follow-up
2012, Annals of OncologyCitation Excerpt :Laparoscopic resection is not recommended because of the need for lymphadenectomy and careful inspection for invasion/metastases. It is a general agreement not to operate on G3 pancreatic NEC, as these tumors are widely metastasized at the timepoint of diagnosis (III, B) [13, 14, 15]. Cytoreductive surgery should be considered when metastatic disease is localized or if >70% of tumor load is thought resectable, which may decrease endocrine and local symptoms and might help to improve systemic treatment.
Appendicular mucocele and endocrine tumor
2012, Presse MedicaleCurrent surgical management of pancreatic endocrine tumor liver metastases
2011, Hepatobiliary and Pancreatic Diseases InternationalSurgical management of liver metastases from gastrointestinal endocrine tumors
2010, Gastroenterologie Clinique et Biologique